Core Points - The document provides information regarding the total number of voting rights and shares of Sanofi as of March 31, 2025 [1] - Sanofi has a registered share capital of €2,452,461,656 and is registered at the Paris Commercial and Companies Registry [1] Summary by Category Voting Rights and Shares - Total number of issued shares as of March 31, 2025, is 1,233,737,221 [1] - The number of real voting rights, excluding treasury shares, is 1,351,370,330 [1] - The theoretical number of voting rights, including treasury shares, is 1,366,610,643 [1]

Core Viewpoint - The vaccine sector is experiencing a decline in stock prices following reports of a significant policy change by the FDA, which will require all new vaccines to undergo placebo-controlled clinical trials before approval [1][2]. Group 1: Market Reaction - Major vaccine companies such as GSK, Sanofi, Merck, AstraZeneca, Pfizer, BioNTech, Moderna, and Novavax have seen stock declines ranging from over 1% to more than 3.7% [1]. - Specifically, Moderna's stock dropped over 3.7%, while BioNTech fell more than 2.5% [1]. Group 2: Regulatory Changes - The FDA plans to implement a new policy requiring all new vaccines to include a placebo group in clinical trials, marking a significant shift in the vaccine approval process [1]. - This policy mandates that new vaccines must undergo safety testing with a control group receiving an inactive substance, such as saline, for comparison [1]. Group 3: Scope of the New Policy - There is uncertainty regarding the definition of "new vaccines," but it is reported that the policy is unlikely to apply to flu vaccines, which have a long-established safety record [2]. - The HHS has not clarified whether vaccines that have already completed safety studies will be subject to re-evaluation under this new policy, focusing mainly on COVID-19 vaccines in their response [2].

Fundraising Activities - In April 2023, a total of 28 fundraising activities were reported, indicating a vibrant investment environment [3] - The "Lilly Asia VI Fund" has been established, becoming the largest market-oriented fundraising biopharmaceutical VC fund in recent years, with a total commitment exceeding RMB 40 billion [5] - Prologis launched its first data center income fund, raising approximately RMB 2.6 billion, marking a significant entry into the data center investment space [7] - The "Kaihui Future Fund" was established in collaboration with L'Oréal and the Shanghai Jing'an District government, focusing on the evolving beauty market in China [8] - A fund initiated by Anhui entrepreneurs raised RMB 3 billion to invest in local science and technology enterprises [10] - Blackstone's latest European real estate fund raised €9.8 billion (approximately $10.6 billion), setting a record for third-party capital commitments in Europe [11] - The "Sanofi-Kaihui Pharmaceutical Innovation Fund" was established with a management scale of approximately RMB 2 billion, focusing on clinical-stage innovative drug pipelines [14] - The "Hubei Highway Development Fund" was launched with a total scale of RMB 30 billion, aimed at supporting modern transportation systems [16] - The Shanghai Biopharmaceutical M&A Fund completed its first closing with a scale of RMB 5 billion, supporting the high-quality development of the biopharmaceutical industry [18] - Eurazeo Capital V successfully raised approximately €3 billion, focusing on high-growth sectors such as technology-enabled business services and healthcare [20] New Fund Establishments - The "Zero One Venture" announced the completion of a new RMB 500 million fund, focusing on intelligent manufacturing and cross-border ventures [22] - The "Hongyi Investment" established a fund in Yixing with a first closing amount of RMB 606 million, targeting new energy and new materials [24] - The "Shaanxi Financial and High-tech Investment Fund" completed its second closing, focusing on semiconductor and AI sectors with a total scale of RMB 1.198 billion [26] - The "Pudong Venture Capital Fund" was launched with a target scale of RMB 1 billion, focusing on the biopharmaceutical industry [28] - Wuxi announced a market-oriented AI industry fund with a total scale of RMB 1 billion to support AI development [30] - The "Changfei Angel Fund" was launched with a total scale of RMB 600 million, focusing on optoelectronic information and AI sectors [32] - The "Low-altitude Economy Fund" in Sichuan was established to invest in eVTOL manufacturing, marking the province's first fund in this area [34] - The "Fangxi Purple Peak Venture Capital Fund" was registered, focusing on technology transfer and innovation in Hefei [36] - The "Yaan Chuan Business Emerging Industry Fund" was established with a registered scale of RMB 100 million, targeting seed and angel investments [39] - The "Wuhan University of Technology Innovation Fund" was launched with an initial fundraising scale of RMB 1 billion [41] Strategic Collaborations - The "AI Angel Fund" was launched by Shanghai Jiao Tong University, focusing on early-stage AI startups with a total scale of RMB 300 million [42] - The "Conch Private Equity Fund" was established, focusing on strategic emerging industries such as new materials and renewable energy [44] - The "Nongyin AIC Fund" was established in Tianjin, focusing on new generation information technology and intelligent manufacturing [56] - The "Hunan Gongrong Dici Venture Capital Fund" was registered, marking the first AIC venture capital fund in Hunan with a scale of RMB 1 billion [58] - The "Qingdao AIC Equity Investment Fund" was established, marking the first AIC fund in the city, with a focus on various strategic emerging industries [60]

周三（4月30日），阿斯麦控股荷兰阿姆斯特丹股价（ASML.NA）收跌0.43%，报582.50欧元，4月份累计下跌3.88%。 诺和诺德哥本哈根股价（NOVOB.DC）收涨2.53%，报435.10（丹麦克朗），4月份累跌7.39%。 | 名称 = | 代码 : | | 开盘 | 흥 | | 涨跌额 # | 涨跌幅 * | | --- | --- | --- | --- | --- | --- | --- | --- | | GSK plc | GSK | 1.483.50 | 1.450.50 | 1.505.50 | 1.427.50 | +51.50 | +3.60% | | 1 Novo Nordisk B | NOVOb | 435.1 | 428.7 | 442.5 | 415.2 | +10.8 | +2.53% | | 赛诺菲 | SASY | 95.90 | 95.00 | 97.31 | 94.88 | +1.67 | +1.77% | | + 雀菓 | NESN | 87.74 | 86.92 | 87.74 | 86.63 | +0.94 | +1.08% | | អត 阿斯利康制药 ...

Annual General Meeting of April 30, 2025 Approval of the financial statements for the fiscal year 2024Distribution of a cash dividend of €3.92 per share, with payment as of May 14, 2025Board composition: renewal of four Directors and ratification of the cooptation of Jean-Paul Kress Paris, April 30, 2025. The Combined General Shareholders’ Meeting of Sanofi was held on April 30, 2025, under the chairmanship of Frédéric Oudéa. All resolutions submitted to the vote were adopted by the shareholders. The Genera ...

Core Viewpoint - The article discusses the strategic investment by XtalPi in Xellar Biosystems, focusing on the integration of AI and organ-on-a-chip technology to enhance drug development and safety evaluation processes, aiming to replace traditional animal testing methods with more efficient and reliable alternatives [1][2][5]. Group 1: Investment and Collaboration - Xellar Biosystems has completed a multi-million yuan strategic financing round led by XtalPi, with continued support from existing investors TianTu Investment and Yayi Capital [1]. - The investment will accelerate the development of Xellar's "3D-Wet-AI" closed-loop system, which integrates organ-on-a-chip technology, wet lab capabilities, and AI algorithms [1][2]. - XtalPi, a leader in AI drug and new materials research, will collaborate with Xellar to address industry challenges such as high-quality biological data generation and AI-assisted toxicology predictions [2][6]. Group 2: Technological Advancements - Xellar's EPIC™ platform combines microfluidic chip technology, disease modeling, and generative AI algorithms, enabling rapid construction of complex microenvironments and high-throughput experiments [4]. - The integration of AI with organ-on-a-chip technology is seen as a transformative approach in life sciences, potentially revolutionizing drug development processes [5][9]. - The collaboration aims to create a seamless connection between in vitro complex models and AI molecular generation and screening algorithms, enhancing drug development efficiency and success rates [2][6]. Group 3: Regulatory Environment - Global regulatory bodies are accelerating the adoption of alternatives to animal testing, with the FDA modernizing its standards to include non-animal methods for new drug IND submissions [3][4]. - Xellar is actively participating in standard validation alongside regulatory agencies, providing predictive analysis services for drug safety and efficacy [4][5]. Group 4: Market Position and Future Outlook - Xellar is positioned as a key player in the AI and organ-on-a-chip space, with a strong foundation in cell biology and disease modeling, which enhances its competitive edge [6][8]. - The partnership with XtalPi is expected to strengthen Xellar's capabilities in automation and intelligent modeling, paving the way for innovative solutions in non-animal testing and precision efficacy prediction [9].

Company Overview - Sanofi has completed the sale of a 50.0% controlling stake in its consumer healthcare business, Opella, to CD&R, while retaining a 48.2% stake [1] - The transaction generated approximately €10 billion in net cash proceeds for Sanofi [1] Opella's Position and Strategy - Opella is now an independent global leader in consumer healthcare, positioned for long-term success with a strong brand portfolio and international reach [3][5] - The company employs over 11,000 people and operates in 100 countries, with 13 manufacturing sites and four development centers [5] - Opella is the third-largest player in the OTC and vitamins, minerals & supplements market, serving over half a billion consumers globally [5] Future Outlook - CD&R aims to support Opella in becoming a global consumer health champion, leveraging its expertise in the consumer health sector [4] - Opella is focused on unlocking its full potential and driving value creation through innovation and exceptional talent [5]

导 语：新政府"权力掮客"麦克道尔是名副其实的猎熊高手，与特朗普多年间一起打过火鸡、麋鹿和野猪。 为了了解小罗伯特·F·肯尼迪（Robert F. Kennedy Jr.），说客切斯·麦克道尔（Ches McDowell）并没有在选举后急着安排会 面，也没有向唐纳德·特朗普（Donald Trump）的就职基金捐款——这些都是华盛顿常见的策略。 相反，麦克道尔（McDowell）通过他的朋友小唐纳德·特朗普（Donald Trump Jr.）获得了肯尼迪（Kennedy）举办的一次猎 鹰活动的邀请。去年十月，在纽约州北部一个阳光明媚的日子里，麦克道尔终于赢得了与这位未来的内阁部长相处的时光 ——他在一次成功的狩猎后喂猎鹰吃老鼠。 "肯尼迪（Kennedy）更有可能与某位美洲原住民萨满成为朋友，而不是与说客交好，"麦克道尔（McDowell）本月早些时 候一边在一家备受共和党官员青睐的牛排馆享用一块带骨肋眼牛排时这样说道。 在2021年1月6日骚乱之后的日子里，许多知名游说人士刻意避开特朗普（Donald Trump），并在2024年竞选期间没有为他 筹集资金。 然而，如今，随着特朗普政府试图通过关税和法律威胁 ...

Core Viewpoint - Regeneron Pharmaceuticals reported disappointing first-quarter 2025 results, with adjusted EPS of $8.22, missing estimates and down 14% year-over-year, primarily due to lower revenues and higher operating expenses [1][2][17] Financial Performance - Total revenues decreased 4% year-over-year to $3 billion, missing the Zacks Consensus Estimate of $3.27 billion, driven by lower sales of Eylea and Libtayo [2][17] - Eylea sales in the U.S. plummeted 39% year-over-year to $736 million, impacted by increased competition and market share loss [4][17] - Total Eylea and Eylea HD sales in the U.S. were $1 billion, down 26% year-over-year, also missing estimates [7][17] - Collaboration revenues from Sanofi and Bayer totaled $1.53 billion, up 20.9% year-over-year, exceeding estimates [8][9] Product Performance - Sanofi's collaboration revenues increased 30% to $1.2 billion, driven by higher Dupixent sales, which rose 19% year-over-year to $3.7 billion [9] - Libtayo sales were $285.1 million, up 8% year-over-year, but missed estimates [10] - Eylea HD generated $307 million in revenues, a 54% increase year-over-year, but total Eylea and Eylea HD sales were still down significantly [6][7] Cost and Expenses - Gross margin decreased to 85% from 89% due to higher inventory write-offs and reserves [11] - Adjusted R&D expenses rose 6% year-over-year to $1.2 billion, while adjusted SG&A expenses decreased 8% to $537 million [11] Shareholder Actions - The board authorized a new share repurchase program for up to $3 billion, with $1.052 billion repurchased in Q1 2025 [12] - A cash dividend of $0.88 per share was declared in April 2025 [12] Regulatory Updates - The FDA approved a label expansion for Dupixent and accepted applications for Eylea HD and other drugs, but also issued complete response letters for some applications [13][14][15][16] Strategic Developments - Regeneron entered a 10-year agreement with Fujifilm Diosynth Biotechnologies to enhance manufacturing capacity in the U.S. [19]

德国思爱普Sap和欧莱雅至少涨2.32%，葛兰素史克、罗氏制药、赛诺菲涨1.63%-1.21%，阿斯利康和雀巢至多涨0.87%。 LVMH集团则收跌2.53%。 | 名称 = | 代码 : | 最新价 | 开营 | 高 | | 低 | | | --- | --- | --- | --- | --- | --- | --- | --- | | Novo Nordisk B H | NOVOb | 424.4 | 408.4 | 429.8 | 406.1 | +10.1 | +2.43% | | I SAP公司 | SAPG | 254.600 | 250.950 | 255.800 | 249.900 | +5.800 | +2.33% | | 欧莱雅 | OREP | 388.00 | 381.85 | 388.00 | 381.30 | +8.80 | +2.32% | | តន GSK plc | લેટાર | 1.432.00 | 1.426.50 | 1.435.50 | 1.404.00 | +23.00 | +1.63% | | + 罗氏制药公司 | ROG | 269.00 | 267.10 ...